Characterization and biological actions of N-terminal truncated forms of glucose-dependent insulinotropic polypeptide

Biochemical and Biophysical Research Communications

Volumn 404, Issue 3, 2011, Pages 870-876

  Kerr, Barry D ^a   Flatt, Anneliese J S ^a   Flatt, Peter R ^a   Gault, Victor A ^a  

^a UNIVERSITY OF ULSTER   (United Kingdom)

Author keywords

GIP antagonist; Glucose lowering; Glucose dependent insulinotropic polypeptide (GIP); Insulin secretion; Ob ob mice

Indexed keywords

ARGININE; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; INSULIN; PHENYLALANINE; VALINE;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; IN VITRO STUDY; INSULIN RELEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; CYCLIC AMP; GASTRIC INHIBITORY POLYPEPTIDE; GLUCOSE; INSULIN; MICE; MICE, INBRED STRAINS; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, GASTROINTESTINAL HORMONE;

MUS;

EID: 78751611186     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.12.077     Document Type: Article

References (32)

1. Brown J.C. Gut Peptides: Biochemistry and Physiology 1994, Raven Press, New York.
2. Irwin N., Flatt P.R., Gault V.A. GIP-based therapeutics for diabetes and obesity. Curr. Chem. Biol. 2008, 2:61-68.
3. Baggio L.L., Drucker D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology 2007, 132:2131-2137.
4. Ehses J.A., Casilla V.R., Doty T., et al. Glucose-dependent insulinotropic polypeptide promotes beta-(INS-1) cell survival via cyclic adenosine monophosphate-mediated caspase-3 inhibition and regulation of p38 mitogen-activated protein kinase. Endocrinology 2003, 144:4433-4445.
5. Trümper A., Trümper K., Hörsch D. Mechanisms of mitogenic and anti-apoptotic signaling by glucose-dependent insulinotropic polypeptide in beta(INS-1)-cells. J. Endocrinol. 2002, 174:233-246.
6. Irwin N., Gault V.A., Flatt P.R. Therapeutic potential of the original incretin hormone glucose-dependent insulinotropic polypeptide: diabetes, obesity, osteoporosis and Alzheimer's disease?. Expert Opin. Investig. Drugs 2010, 19:1039-1048.
7. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide-1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
8. Meier J.J., Nauck M.A., Kranz D., et al. Secretion, degradation, and elimination of glucagon-like peptide-1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects. Diabetes 2004, 53:654-662.
9. Deacon C.F. Circulation and degradation of GIP and GLP-1. Horm. Metab. Res. 2004, 36:761-765.
10. Gault V.A., Parker J.C., Harriott P., et al. Evidence that the major metabolic degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J. Endocrinol. 2002, 175:525-533.
11. Deacon C.F., Plamboeck A., Rosenkilde M.M., et al. GIP(3-42) does not antagonise insulinotropic effects of GIP at physiological concentrations. Am. J. Physiol. Endocrinol. Metab. 2006, 291:E468-E475.
12. Parker J.C., Lavery K.S., Irwin N., et al. Effects of sub-chronic exposure to naturally occurring N-terminally truncated metabolites of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), GIP(3-42) and GLP-1(9-36)amide, on insulin secretion and glucose homeostasis in ob/ob mice. J. Endocrinol. 2006, 191:93-100.
13. Gault V.A., Harriott P., Flatt P.R., O'Harte F.P. Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide. Biosci. Rep. 2002, 22:523-528.
14. Gelling R.W., Coy D.H., Pederson R.A., et al. GIP(6-30amide) contains the high affinity binding region of GIP and is a potent inhibitor of GIP1-42 action in vitro. Regul. Pept. 1997, 69:151-154.
15. Tseng C.C., Zhang X.Y., Wolfe M.M. Effect of GIP and GLP-1 antagonists on insulin release in the rat. Am. J. Physiol. 1996, 276:E1049-E1054.
16. Gault V.A., O'Harte F.P., Harriott P., Flatt P.R. Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide. Biochem. Biophys. Res. Commun. 2002, 290:1420-1426.
17. 3)GIP administration improves glucose tolerance and ameliorates insulin resistance and abnormalities if islet structure in obesity-related diabetes. Diabetes 2005, 54:2436-2446.
18. Gault V.A., McClean P.L., Cassidy R.S., et al. Chemical gastric inhibitory polypeptide receptor antagonism protects against obesity, insulin resistance, glucose intolerance and associated disturbances in mice fed high-fat and cafeteria diets. Diabetologia 2007, 50:1752-1762.
19. Miyawaki K., Yamada Y., Ban N., et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat. Med. 2002, 8:738-742.
20. 3)GIP improves metabolic status in high-fat-fed mice. Diabetes Obes. Metab. 2010, 12:744-751.
21. Alana I., Malthouse J.P., O'Harte F.P., Hewage C.M. The bioactive conformation of glucose-dependent insulinotropic polypeptide by NMR and CD spectroscopy. Proteins 2007, 68:92-99.
22. Alana I., Parker J.C., Gault V.A., et al. NMR and alanine scan studies of glucose-dependent insulinotropic polypeptide in water. J. Biol. Chem. 2006, 281:16370-16376.
23. Malde A.K., Srivastava S.S., Coutinho E.C. Understanding interactions of gastric inhibitory polypeptide (GIP) with its G-protein coupled receptor through NMR and molecular modelling. J. Pept. Sci. 2007, 13:287-300.
24. Tikhele S.H., Pissurlenkar R.R., Srivastava S.S., et al. Mapping interactions of gastric inhibitory polypeptide with GIPR N-terminus using NMR and molecular dynamics simulations. J. Pept. Sci. 2010, 16:383-391.
25. McClenaghan N.H., Barnett C.R., Ah-Sing E., et al. Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion. Diabetes 1996, 45:1132-1140.
26. Flatt P.R., Bailey C.J. Abnormal plasma glucose and insulin responses in heterozygous lean (ob/+) mice. Diabetologia 1981, 20:573-577.
27. Bailey C.J., Flatt P.R., Atkins T.W. Influence of genetic background and age on the expression of the obese hyperglycaemic syndrome in Aston ob/ob mice. Int. J. Obes. 1982, 6:11-21.
28. Stevens J.F. Determination of glucose by an automatic analyser. Clin. Chem. Acta 1971, 32:199-201.
29. Usdin T.B., Mezey E., Button D.C., et al. Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain. Endocrinology 1993, 133:2861-2870.
30. Kerr B.D., Irwin N., O'Harte F.P., et al. Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Biochem. Pharmacol. 2009, 78:1008-1016.
31. Carlquist M., Maletti M., Jornvall H., Mutt V. A novel form of gastric inhibitory polypeptide (GIP) isolated from bovine intestine using a radioreceptor assay. Fragmentation with staphylococcal protease results in GIP1-3 and GIP4-42, fragmentation with enterokinase in GIP1-16 and GIP17-42. Eur. J. Biochem. 1984, 145:573-577.
32. Agerberth B., Boman A., Andersson M., et al. Isolation of three antibacterial peptides from pig intestine: gastric inhibitory polypeptide (7-42), diazepam-binding inhibitor (32-86) and a novel factor, peptide 3910. Eur. J. Biochem. 1993, 216:623-629.